4-(8-azabicyclo[3.2.1]oct-8-yl)benzonitrile | 852241-38-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(8-azabicyclo[3.2.1]oct-8-yl)benzonitrile
• 英文别名: 4-(8-Azabicyclo[3.2.1]octan-8-yl)benzonitrile
• CAS: 852241-38-4
• 化学式: C₁₄H₁₆N₂
• 分子量: 212.294
• InChiKey: XZQTZXTZSNICBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  383.3±25.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(8-azabicyclo[3.2.1]oct-8-yl)benzonitrile 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  In Vitro Structure−Activity Relationship and In Vivo Characterization of 1-(Aryl)-3-(4-(amino)benzyl)urea Transient Receptor Potential Vanilloid 1 Antagonists

  摘要：

  The synthesis and structure-activity relationship of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 (TRPV1) antagonists are described. A variety of cyclic amine substituents are well tolerated at the 4-position of the benzyl group on compounds containing either an isoquinoline or indazole heterocyclic core. These compounds are potent antagonists of capsaicin activation of the TRPV1 receptor in vitro. Analogues, such as compound 45, have been identified that have good in vivo activity in animal models of pain. Further optimization of 45 resulted in compound 58 with substantially improved microsome stability and oral bioavailability, as well as in vivo activity.

  DOI：

  10.1021/jm070276i
• 作为产物：
  描述：

  对氟苯腈 生成 4-(8-azabicyclo[3.2.1]oct-8-yl)benzonitrile
  参考文献：
  名称：

  Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

  摘要：

  式（I）的化合物是新颖的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。

  公开号：

  US20040157849A1

文献信息

• FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
  申请人：ABBOTT LABORATORIES

  公开号：EP1660455B1

  公开（公告）日：2008-10-15
• US6933311B2
  申请人：——

  公开号：US6933311B2

  公开（公告）日：2005-08-23
• [EN] FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR<br/>[FR] COMPOSES AZABICYCLIQUES FUSIONNES INHIBANT LE RECEPTEUR VANILLOIDE DE SOUS-TYPE 1 (VR1)
  申请人：ABBOTT LAB

  公开号：WO2005016890A1

  公开（公告）日：2005-02-24

  Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
• [EN] DYES, COMPOSITIONS AND RELATED METHODS OF USE<br/>[FR] COLORANTS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：HARVARD COLLEGE

  公开号：WO2010054183A2

  公开（公告）日：2010-05-14

  Donor-acceptor dyes, compositions, and related methods of use are described herein.
• Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
  申请人：——

  公开号：US20040157849A1

  公开（公告）日：2004-08-12

  Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  式（I）的化合物是新颖的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。